New hepatitis drug to cost more in middle income nations; activists cry foul
Pharma company’s strategy of different prices for different countries to affect quality treatment of 185 million people infected with …
Effective oral drug for Hepatitis C approved by European agencies
Various patent barriers hinder its availability and affordability, especially in countries with high burden of disease